ZyVersa Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $388.60K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Sep 30, 2025 | Nov 19, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 3, 2023 | Before market open | – | – | – |
Press releases
Announcements ZyVersa Therapeutics filed with the SEC
Therapeutics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2023 Corporate and Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
Other events · EX-99.1 to Form 8-K
Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
(this “ Agreement ”) is dated as of July 20, 2022 1 ,
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Securities Purchase Agreement (this “ Agreement ”) is dated as of December 12, 2022, between Larkspur Health Acquisition
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.3 to Form 8-K
JOINT PRESS RELEASE DATED JULY 20, 2022
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION DATED JULY 16, 2022
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 7, 2022
Other events · EX-99.1 to Form 8-K
PRESS RELEASE FOR THE PRICING OF THE IPO, DATED DECEMBER 20, 2021
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PRESS RELEASE FOR THE CLOSING OF THE IPO, DATED DECEMBER 23, 2021
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K